NasdaqGS:LUNG

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. More Details


Snowflake Analysis

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has Pulmonx's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LUNG is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: Insufficient data to determine LUNG's volatility change over the past year.


Market Performance


7 Day Return

-1.4%

LUNG

-2.3%

US Medical Equipment

-3.6%

US Market


1 Year Return

n/a

LUNG

33.8%

US Medical Equipment

36.4%

US Market

Return vs Industry: Insufficient data to determine how LUNG performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how LUNG performed against the US Market.


Shareholder returns

LUNGIndustryMarket
7 Day-1.4%-2.3%-3.6%
30 Day-5.6%-0.5%0.9%
90 Day3.3%6.7%6.7%
1 Yearn/a34.9%33.8%39.4%36.4%
3 Yearn/a75.6%71.1%53.4%43.5%
5 Yearn/a149.9%131.5%117.3%93.0%

Long-Term Price Volatility Vs. Market

How volatile is Pulmonx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pulmonx undervalued compared to its fair value and its price relative to the market?


Share Price vs. Fair Value

Below Fair Value: LUNG ($56.83) is trading above our estimate of fair value ($26.18)

Significantly Below Fair Value: LUNG is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: LUNG is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: LUNG is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LUNG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LUNG has negative assets, so we can't compare its PB Ratio to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Pulmonx forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

38.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LUNG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LUNG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LUNG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LUNG's revenue (28.9% per year) is forecast to grow faster than the US market (10.4% per year).

High Growth Revenue: LUNG's revenue (28.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LUNG's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Pulmonx performed over the past 5 years?

-37.0%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: LUNG is currently unprofitable.

Growing Profit Margin: LUNG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if LUNG's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare LUNG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LUNG is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.8%).


Return on Equity

High ROE: LUNG has a negative Return on Equity (-3887.75%), as it is currently unprofitable.


Next Steps

Financial Health

How is Pulmonx's financial position?


Financial Position Analysis

Short Term Liabilities: LUNG's short term assets ($55.6M) exceed its short term liabilities ($15.2M).

Long Term Liabilities: LUNG's short term assets ($55.6M) exceed its long term liabilities ($55.4M).


Debt to Equity History and Analysis

Debt Level: LUNG's debt to equity ratio (6627.6%) is considered high.

Reducing Debt: Insufficient data to determine if LUNG's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LUNG has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LUNG has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 20.9% each year.


Next Steps

Dividend

What is Pulmonx current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LUNG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LUNG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LUNG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LUNG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LUNG's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Glen French (58 yo)

6.17yrs

Tenure

US$1,122,487

Compensation

Mr. Glendon E. French, also known as Glen, has been Chief Executive Officer, President and Director at Pulmonx Corporation since December 2014 and also serves as its Secretary. From January 2014 to Novembe...


CEO Compensation Analysis

Compensation vs Market: Glen's total compensation ($USD1.12M) is below average for companies of similar size in the US market ($USD3.66M).

Compensation vs Earnings: Insufficient data to compare Glen's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Glendon French
CEO, President6.17yrsUS$1.12m3.58%
$ 72.7m
Derrick Sung
Chief Financial Officer1.75yrsUS$428.90k0.64%
$ 13.0m
Geoffrey Rose
Chief Commercial Officerno dataUS$473.31k0.32%
$ 6.5m
Sri Radhakrishnan
Chief Technical Officer1.08yrsno datano data
Martin Schneider
Vice President of Finance and Administrationno datano datano data
Lauren Cristina
Vice President of Finance & Administration (U.S.)no datano datano data
Jérôme Erath
Senior VP & GM of Europe Middle-East & Africano datano datano data
David Renzi
Senior Vice President of Sales - North Americano datano datano data

1.8yrs

Average Tenure

58yo

Average Age

Experienced Management: LUNG's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Glendon French
CEO, President6.17yrsUS$1.12m3.58%
$ 72.7m
Dana Mead
Independent Chairperson of the Board1.33yrsUS$28.55k0.074%
$ 1.5m
Richard Ferrari
Independent Director14yrsno data0.045%
$ 919.9k
Staffan Lindstrand
Independent Director11yrsno datano data
Georgia Garinois-Melenikiotou
Independent Director0.33yrno data0.074%
$ 1.5m
Thomas Burns
Independent Director0.33yrno datano data
Daniel Florin
Independent Director1.08yrsUS$26.05k0.044%
$ 897.4k

1.3yrs

Average Tenure

59yo

Average Age

Experienced Board: LUNG's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: LUNG only recently listed within the past 12 months.


Top Shareholders

Company Information

Pulmonx Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pulmonx Corporation
  • Ticker: LUNG
  • Exchange: NasdaqGS
  • Founded: 1995
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$2.027b
  • Shares outstanding: 35.67m
  • Website: https://pulmonx.com

Number of Employees


Location

  • Pulmonx Corporation
  • 700 Chesapeake Drive
  • Redwood City
  • California
  • 94063
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LUNGNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDOct 2020
4NIBST (Boerse-Stuttgart)YesCommon SharesDEEUROct 2020

Biography

Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases....


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/02/28 00:42
End of Day Share Price2021/02/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.